Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

6.9K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.9K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

16.7K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probabilistic Lesion Mapping to Optimize Thalamotomy Targets for Focal Hand Dystonia.

Annals of neurology·2026
Same author

Deep brain stimulation for epilepsy: optimal targeting and clinical outcomes.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Optimal focused ultrasound lesion location in essential tremor.

Science advances·2025
Same author

A Posterior Approach for Combined Targeting of the Centromedian Nucleus and Pulvinar for Responsive Neurostimulation.

Operative neurosurgery (Hagerstown, Md.)·2025
Same author

Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.

The journal of allergy and clinical immunology. In practice·2024
Same author

Tremor Severity and Operative Parameters Predict Imbalance in Patients Undergoing Focused Ultrasound Thalamotomy.

Movement disorders clinical practice·2024

Related Experiment Video

Updated: Feb 17, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.9K

Cancer-type dependent expression of CK2 transcripts.

Melissa M J Chua1, Migi Lee1, Isabel Dominguez1

  • 1Department of Medicine, Boston University School of Medicine, Boston MA, United States of America.

Plos One
|December 6, 2017
PubMed
Summary
This summary is machine-generated.

Cancer cells exhibit altered expression of the serine-threonine kinase CK2. This study reveals widespread CK2 transcript dysregulation across various cancers, impacting patient survival differently depending on cancer type.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Experiment Videos

Last Updated: Feb 17, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genomics

Background:

  • Aberrant protein expression is a hallmark of cancer, with the oncogenic serine-threonine kinase CK2 being frequently implicated.
  • Previous studies indicated increased CK2 transcript levels in several major cancer types, but also noted downregulation in some.
  • The comprehensive transcriptomic landscape of CK2 in all human cancers remained largely unexplored.

Purpose of the Study:

  • To investigate the dysregulation of all CK2 transcripts across a wide spectrum of human cancers.
  • To determine the correlation between CK2 transcript levels and patient survival outcomes.
  • To identify specific cancer types exhibiting unique CK2 expression patterns.

Main Methods:

  • Utilized the Oncomine database for comprehensive analysis of CK2 transcript expression across diverse cancer types.
  • Compared CK2 transcript levels in cancerous tissues versus normal tissues.
  • Correlated CK2 transcript expression levels with patient survival data.

Main Results:

  • Confirmed widespread dysregulation of CK2 transcripts in numerous cancers, including upregulation (e.g., cervical cancer), downregulation (e.g., testicular cancer), and mixed patterns (e.g., sarcoma).
  • Observed CK2 transcript dysregulation in pre-cancerous benign lesions (e.g., Barrett's esophagus).
  • Demonstrated a correlation between CK2 transcript upregulation and reduced patient survival in most significant cases, with notable exceptions in glioblastoma and renal cell carcinoma where upregulation correlated with improved survival.

Conclusions:

  • CK2 gene expression is highly variable across different cancer types, presenting complex patterns of upregulation and downregulation.
  • CK2 transcript dysregulation can occur early, even in benign lesions, suggesting a role in cancer initiation.
  • The impact of CK2 transcript levels on patient survival is context-dependent, varying significantly between cancer types, highlighting the need for tailored therapeutic strategies.